Conference Coverage
April 4, 2017
Expedited FDA approval plays dominant role in drug approvals
Last year was a banner year for generic drug approvals by the FDA.
Find out what's in store for 2017
 
ADVERTISEMENT
 
Trends to watch in the pharmaceutical marketplace
From public furor over price hikes to the loss of patent protections for blockbuster drugs, big changes are afoot.
Read more
 
Incremental clinical advances for Duchenne Muscular Dystrophy
Just last year, the FDA approved Exondys 51 (eteplirsen) for DMD, over the recommendations of FDA scientists and an external scientific advisory committee.
Read more
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

 
>>>>>>>